CoChat

Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma

Müller, Michael, Rösch, Lisa, Najafi, Sara, Gatzweiler, Charlotte, Ridinger, Johannes, Gerloff, Xenia F., Jones, David T. W., Baßler, Jochen, Kreth, Sina, Stainczyk, Sabine, Frese, Karen, Meder, Benjamin, Westermann, Frank, Milde, Till, Peterziel, Heike, Witt, Olaf, Oehme, Ina · 2021 · Cancers
Cited by 14

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

APR-246 (Eprenetapopt/PRIMA-1Met) is a very potent anti-cancer drug in clinical trials and was initially developed as a p53 refolding agent. As an alternative mode of action, the elevation of reactive oxygen species (ROS) has been proposed. Through an in silico analysis, we investigated the responses of approximately 800 cancer cell lines (50 entities; Cancer Therapeutics Response Portal, CTRP) to APR-246 treatment. In particular, neuroblastoma, lymphoma and acute lymphocytic leukemia cells were highly responsive. With gene expression data from the Cancer Cell Line Encyclopedia (CCLE; n = 883) and patient samples (n = 1643) from the INFORM registry study, we confirmed that these entities express low levels of SLC7A11, a previously described predictive biomarker for APR-246 responsiveness. Combining the CTRP drug response data with the respective CCLE gene expression profiles, we defined a novel gene signature, predicting the effectiveness of APR-246 treatment with a sensitivity of 90% and a specificity of 94%. We confirmed the predicted APR-246 sensitivity in 8/10 cell lines and in ex vivo cultures of patient samples. Moreover, the combination of ROS detoxification-impeding APR-246 with approved HDAC-inhibitors, known to elevate ROS, substantially increased APR-246 sensitivity in cell cultures and in vivo in two zebrafish neuroblastoma xenograft models. These data provide evidence that APR-246, in combination with HDAC-inhibitors, displays a novel potent targeted treatment option for neuroblastoma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13174476

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 51

  1. Brodeur, 2003, Neuroblastoma: Biological insights into a clinical enigma, Nat. Rev. Cancer, 3, 203, 10.1038/nrc1014 · DOI · Paper page
  2. Cohn, 2009, The International Neuroblastoma Risk Group (INRG) classification system: An INRG task force report, J. Clin. Oncol., 27, 289, 10.1200/JCO.2008.16.6785 · DOI · Paper page
  3. Monclair, 2009, The International Neuroblastoma Risk Group (INRG) staging system: An INRG task force report, J. Clin. Oncol., 27, 298, 10.1200/JCO.2008.16.6876 · DOI · Paper page
  4. Wasylishen, A.R., and Lozano, G. (2016). Attenuating the p53 pathway in human cancers: Many means to the same end. Cold Spring Harb Perspect. Med., 6. · DOI · Paper page
  5. Ackermann, 2018, A mechanistic classification of clinical phenotypes in neuroblastoma, Science, 362, 1165, 10.1126/science.aat6768 · DOI · Paper page
  6. Tweddle, 2001, p53 cellular localization and function in neuroblastoma: Evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells, Am. J. Pathol., 158, 2067, 10.1016/S0002-9440(10)64678-0 · doi:10.1016/s0002-9440(10)64678-0
  7. Isaacs, 1998, Differential subcellular p53 localization and function in N- and S-type neuroblastoma cell lines, Cell Growth Differ., 9, 545
  8. Moll, 1995, Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors, Proc. Natl. Acad. Sci. USA, 92, 4407, 10.1073/pnas.92.10.4407 · DOI · Paper page
  9. Duffy, 2017, Mutant p53 as a target for cancer treatment, Eur. J. Cancer, 83, 258, 10.1016/j.ejca.2017.06.023 · DOI · Paper page
  10. Storz, 2005, Reactive oxygen species in tumor progression, Front. Biosci., 10, 1881, 10.2741/1667 · DOI · Paper page
  11. Wang, 2018, An acquired vulnerability of drug-resistant melanoma with therapeutic potential, Cell, 173, 1413, 10.1016/j.cell.2018.04.012 · DOI · Paper page
  12. Koeneke, 2015, HDAC family members intertwined in the regulation of autophagy: A druggable vulnerability in aggressive tumor entities, Cells, 4, 135, 10.3390/cells4020135 · DOI · Paper page
  13. Ridinger, J., Koeneke, E., Kolbinger, F.R., Koerholz, K., Mahboobi, S., Hellweg, L., Gunkel, N., Miller, A.K., Peterziel, H., and Schmezer, P. (2018). Dual role of HDAC10 in lysosomal exocytosis and DNA repair promotes neuroblastoma chemoresistance. Sci. Rep., 8. · DOI
  14. Fabian, 2014, GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3, Cancer Res., 74, 2604, 10.1158/0008-5472.CAN-13-1904 · DOI
  15. Ecker, J., Oehme, I., Mazitschek, R., Korshunov, A., Kool, M., Hielscher, T., Kiss, J., Selt, F., Konrad, C., and Lodrini, M. (2015). Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. Acta Neuropathol. Commun., 3. · DOI
  16. Oehme, 2013, Histone deacetylase 10-promoted autophagy as a druggable point of interference to improve the treatment response of advanced neuroblastomas, Autophagy, 9, 2163, 10.4161/auto.26450 · DOI
  17. Witt, 2009, Targeting histone deacetylases in neuroblastoma, Curr. Pharm. Des., 15, 436, 10.2174/138161209787315774 · DOI
  18. Kolbinger, 2018, The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines, Arch. Toxicol., 92, 2649, 10.1007/s00204-018-2234-8 · DOI
  19. Milde, 2010, HDAC5 and HDAC9 in medulloblastoma: Novel markers for risk stratification and role in tumor cell growth, Clin. Cancer Res., 16, 3240, 10.1158/1078-0432.CCR-10-0395 · DOI · Paper page
  20. El-Naggar, A.M., Somasekharan, S.P., Wang, Y., Cheng, H., Negri, G.L., Pan, M., Wang, X.Q., Delaidelli, A., Rafn, B., and Cran, J. (2019). Class I HDAC inhibitors enhance YB-1 acetylation and oxidative stress to block sarcoma metastasis. EMBO Rep., 20. · DOI
  21. Anastas, J.N., Zee, B.M., Kalin, J.H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M.A., Giera, S., Gillespie, S.M., and Das, J. (2019). Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Cancer Cell, 36. · DOI · Paper page
  22. Witt, 2012, Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia, Klin. Padiatr., 224, 398, 10.1055/s-0032-1323692 · doi:10.1055/s-0032-1323692
  23. (2021, May 08). National Center for Biotechnology Information. PubChem Compound Summary for CID 322968, Prima-1, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Prima-1.
  24. (2021, May 08). National Center for Biotechnology Information. PubChem Compound Summary for CID 52918385, Prima-1met, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Prima-1met.
  25. (2021, May 08). National Center for Biotechnology Information. PubChem Compound Summary for CID 322973, 2-Methylenequinuclidin-3-one, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/2-Methylenequinuclidin-3-one.
  26. Jemaà, M., Sime, W., Abassi, Y., Lasorsa, V.A., Bonne Køhler, J., Michaelis, M., Cinatl, J., Capasso, M., and Massoumi, R. (2020). Gene expression signature of acquired chemoresistance in neuroblastoma cells. Int. J. Mol. Sci., 21. · DOI
  27. Sapio, R.T., Nezdyur, A.N., Krevetski, M., Anikin, L., Manna, V.J., Minkovsky, N., and Pestov, D.G. (2017). Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner. Sci. Rep., 7. · DOI
  28. Worst, 2016, Next-generation personalized medicine for high-risk pediatric cancer patients—The INFORM pilot study, Eur. J. Cancer, 65, 91, 10.1016/j.ejca.2016.06.009 · DOI · Paper page
  29. Lin, 2017, A protocol for rapid post-mortem cell culture of Diffuse Intrinsic Pontine Glioma (DIPG), J. Vis. Exp., 9, 5233
  30. Fischer, 2005, Reliable transcript quantification by real-time reverse transcriptase-polymerase chain reaction in primary neuroblastoma using normalization to averaged expression levels of the control genes HPRT1 and SDHA, J. Mol. Diagn., 7, 89, 10.1016/S1525-1578(10)60013-X · DOI
  31. Witt, 2003, Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin, Blood, 101, 2001, 10.1182/blood-2002-08-2617 · DOI · Paper page
  32. Wrobel, J.K., Najafi, S., Ayhan, S., Gatzweiler, C., Krunic, D., Ridinger, J., Milde, T., Westermann, F., Peterziel, H., and Meder, B. (2020). Rapid in vivo validation of HDAC inhibitor-based treatments in neuroblastoma zebrafish xenografts. Pharmaceuticals, 13. · DOI
  33. Aksoy, B.A., Dancík, V., Smith, K., Mazerik, J.N., Ji, Z., Gross, B., Nikolova, O., Jaber, N., Califano, A., and Schreiber, S.L. (2017). CTD2 Dashboard: A searchable web interface to connect validated results from the Cancer Target Discovery and Development Network. Database, 11. · DOI
  34. Rees, 2016, Correlating chemical sensitivity and basal gene expression reveals mechanism of action, Nat. Chem. Biol., 12, 109, 10.1038/nchembio.1986 · DOI · Paper page
  35. Basu, 2013, An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules, Cell, 154, 1151, 10.1016/j.cell.2013.08.003 · DOI · Paper page
  36. Ianevski, 2020, SynergyFinder 2.0: Visual analytics of multi-drug combination synergies, Nucleic Acids Res., 48, W488, 10.1093/nar/gkaa216 · DOI · Paper page
  37. Lu, 2016, PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK, Oncotarget, 7, 83017, 10.18632/oncotarget.12940 · DOI
  38. Aryee, 2013, Variability in functional p53 reactivation by PRIMA-1Met/APR-246 in Ewing sarcoma, Br. J. Cancer, 109, 2696, 10.1038/bjc.2013.635 · DOI
  39. Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  40. Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Shibata, H., Kanamaru, R., and Ishioka, C. (2003). Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci. USA, 100. · DOI · Paper page
  41. Sultana, 2019, Zinc dependent histone deacetylase inhibitors in cancer therapeutics: Recent update, Curr. Med. Chem., 26, 7212, 10.2174/0929867325666180530094120 · DOI
  42. Mlakar, 2019, PRIMA-1(MET)-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level, J. Exp. Clin. Cancer Res., 38, 69, 10.1186/s13046-019-1066-6 · DOI · Paper page
  43. Demir, 2020, Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia, Haematologica, 105, 170, 10.3324/haematol.2018.199364 · DOI
  44. Nikolaev, A., Fiveash, J.B., and Yang, E.S. (2020). Combined targeting of mutant p53 and Jumonji family histone demethylase augments therapeutic efficacy of radiation in H3K27M DIPG. Int. J. Mol. Sci., 21. · doi:10.20944/preprints201912.0076.v1
  45. Urdiciain, 2021, APR-246 combined with 3-deazaneplanocin A, panobinostat or temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells, Int. J. Oncol., 58, 312, 10.3892/ijo.2021.5177 · DOI
  46. van Groningen, T., Akogul, N., Westerhout, E.M., Chan, A., Hasselt, N.E., Zwijnenburg, D.A., Broekmans, M., Stroeken, P., Haneveld, F., and Hooijer, G.K.J. (2019). A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat. Commun., 10. · DOI · Paper page
  47. Groningen, 2017, Neuroblastoma is composed of two super-enhancer-associated differentiation states, Nat. Genet., 49, 1261, 10.1038/ng.3899 · DOI · Paper page
  48. Cen, J., Zhang, L., Liu, F., Zhang, F., and Ji, B.S. (2016). Long-term alteration of reactive oxygen species led to multidrug resistance in MCF-7 cells. Oxid Med. Cell Longev., 2016. · DOI
  49. Waghela, 2021, Upregulation of NOX-2 and Nrf-2 promotes 5-Fluorouracil resistance of human colon carcinoma (HCT-116) cells, Biochemistry, 86, 262
  50. Zhao, 2021, RIP3 mediates TCN-induced necroptosis through activating mitochondrial metabolism and ROS production in chemotherapy-resistant cancers, Am. J. Cancer Res., 11, 729
  51. Halliwell, 2014, Cell culture, oxidative stress, and antioxidants: Avoiding pitfalls, Biomed. J., 37, 99

Cited by

See all 14

Metadata

Authors
Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I.
Affiliations
  • Hopp Children’s Cancer Center Heidelberg (KiTZ), 69120 Heidelberg, Germany
  • Biochemistry Center, Heidelberg University, 69120 Heidelberg, Germany
  • Institute for Cardiomyopathies Heidelberg, Heidelberg University, 69120 Heidelberg, Germany
Venue
Cancers
Publisher
MDPI AG
Published
2021-09-05
Volume
13
Issue
17
Pages
4476
ISSN
2072-6694
Cited by
14
References
15
Language
en
Funders
  • Mildred Scheel Doctoral Scholarship (70113124)
  • SFB 1389-UNITE Glioblastoma (Work Package A02)
  • H.W. & J. Hector Foundation (M91)
  • Ministry of Rural Affairs and Consumer Protection Baden-Wuerttemberg (ID 4781)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. https://app.cochat.ai/papers/10.3390/cancers13174476
The paper
Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I. (2021). Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers. https://doi.org/10.3390/cancers13174476

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.